Neurodevelopmental Disorder With Growth Impairment Quadriparesis And Poor Or Absent Speech C6065911
A severe neurodevelopmental disorder affecting movement, growth, and speech development. Children may have limited mobility and speech ability. Care involves multiple therapies to support development and daily function.
Key facts at a glance
- ICD-10
- G40.909
- ICD-11
- 8A00.0
- Body system
- neurologic
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Quadriparesis
Generalized symptoms
(neurologic)Significant symptoms that substantially affect daily functioning.
Frequency: Common at all stages
Growth impairment
(growth)Poor/absent speech
(neurologic)Developmental delay
(neurologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Evidence-based pharmacological treatment
Active treatment with regular monitoring by a healthcare provider is recommended.
Intensive motor rehabilitation
Comprehensive physical therapy addressing quadriparesis through strength training, range of motion exercises, and functional mobility work to maximize physical potential.
Growth assessment and intervention
Specialized endocrine evaluation and management of growth impairment through monitoring, nutritional optimization, and consideration of growth-promoting interventions when appropriate.
Additional treatment options
Communication and speech support
Speech-language pathology services addressing absent or poor speech through alternative communication systems, speech-generating devices, and therapeutic interventions.
psychologicalNutritional optimization
Medical nutrition therapy ensuring adequate caloric intake, proper weight management, and micronutrient support for individuals with growth impairment and potential feeding difficulties.
dietaryAquatic therapy
Water-based therapy providing resistance training with reduced joint stress, supporting motor development and functional improvement in a low-impact environment.
complementaryWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Neurodevelopmental Disorder With Growth Impairment Quadriparesis And Poor Or Absent Speech C6065911?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalMedication Comparisons
Compare medications used to treat Neurodevelopmental Disorder With Growth Impairment Quadriparesis And Poor Or Absent Speech C6065911. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy